Actinium Pharmaceuticals Inc (ATNM)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $51.56M
Last updated: Nov 17, 2026 at 11:04 AM ET
Actinium Pharmaceuticals Inc (ATNM) Financials: Revenue, Profit and Cash Flow
Actinium Pharmaceuticals reported revenue of $90.00K for the fiscal year ended Dec 31, 2025. That year, net income was -$33.89M with a net margin of -37652.2%, operating cash flow was -$24.58M and free cash flow was -$24.68M. The quarter ended Jun 30, 2026 had revenue of $35.00M and net income of $27.90M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $90.00K | N/A | 100.0% | -40274.4% | -37652.2% |
| Dec 2024 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2023 | $81.00K | -92.1% | 100.0% | -64098.8% | -60269.1% |
| Dec 2022 | $1.03M | -55.0% | 100.0% | -3311.1% | -3205.5% |
| Dec 2021 | $2.29M | N/A | 100.0% | -1091.1% | -1082.8% |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90.00K | $0 | $81.00K | $1.03M | $2.29M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $90.00K | $0 | $81.00K | $1.03M | $2.29M | $0 | $0 | $0 | $0 | $0 |
| Research and development | $21.12M | $30.05M | $38.67M | $23.14M | $18.03M | $16.09M | $16.55M | $17.09M | $17.72M | $17.83M |
| Operating income | -$36.25M | -$42.12M | -$51.92M | -$34.10M | -$24.96M | -$22.39M | -$22.07M | -$23.83M | -$26.91M | -$26.85M |
| Net income | -$33.89M | -$38.24M | -$48.82M | -$33.02M | -$24.77M | -$22.21M | -$21.90M | -$23.65M | -$26.60M | -$24.32M |
| EBITDA | -$35.43M | -$41.31M | -$51.13M | -$33.41M | -$24.44M | -$21.95M | -$21.48M | -$23.78M | -$26.55M | -$24.24M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.00M | $0 | $0 | $90.00K | $0 | $0 | $810.00K | $0 | $0 | $0 | $81.00K | $0 |
| Gross profit | $35.00M | $0 | $615.00K | $90.00K | $0 | $0 | -$204.00K | $0 | $0 | $0 | $81.00K | $0 |
| Operating income | $27.57M | -$5.90M | -$6.41M | -$5.69M | -$7.50M | -$16.64M | -$7.50M | -$12.60M | -$12.42M | -$9.60M | -$10.34M | -$14.35M |
| Net income | $27.90M | -$5.52M | -$5.94M | -$5.13M | -$6.88M | -$15.94M | -$6.65M | -$11.57M | -$11.35M | -$8.67M | -$9.32M | -$13.28M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $722.00K by $47.28M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $51.77M | $76.90M | $81.44M | $114.19M | $80.39M | $66.40M | $11.67M | $14.89M | $18.34M | $22.53M |
| Current assets | $49.38M | $74.51M | $78.26M | $110.94M | $79.75M | $64.92M | $10.09M | $14.33M | $17.84M | $22.39M |
| Cash and equivalents | $48.00M | $72.90M | $76.68M | $108.91M | $77.83M | $63.56M | $9.25M | $13.67M | $17.40M | $20.52M |
| Total liabilities | $43.94M | $44.14M | $45.07M | $47.71M | $6.84M | $5.08M | $6.03M | $6.08M | $4.67M | $4.52M |
| Short-term debt | $722.00K | $580.00K | $541.00K | $10.13M | $307.00K | $4.34M | $381.00K | $249.24K | $0 | $300.68K |
| Shareholder equity | $7.83M | $32.76M | $36.38M | $66.48M | $73.55M | $61.32M | $5.64M | $8.81M | $13.67M | $18.01M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $40.16M | $45.44M | $51.77M | $56.15M | $63.02M | $68.65M | $76.90M | $82.11M | $89.86M | $88.35M | $81.44M | $88.94M |
| Total liabilities | $9.86M | $43.13M | $43.94M | $42.37M | $44.00M | $42.95M | $44.14M | $43.91M | $46.03M | $44.49M | $45.07M | $45.36M |
| Cash and equivalents | $36.47M | $42.13M | $48.00M | $53.39M | $59.93M | $65.33M | $72.90M | $78.66M | $86.04M | $84.06M | $76.68M | $82.98M |
| Shareholder equity | $30.30M | $2.30M | $7.83M | $13.78M | $19.01M | $25.69M | $32.76M | $38.21M | $43.84M | $43.86M | $36.38M | $43.58M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$24.58M | -$33.07M | -$47.34M | $8.64M | -$20.87M | -$21.62M | -$21.46M | -$20.57M | -$21.55M | -$20.79M |
| Capital expenditures | $104.00K | $11.00K | $153.00K | $366.00K | $133.00K | $253.00K | $64.00K | $96.09K | $24.74K | $59.96K |
| Free cash flow | -$24.68M | -$33.08M | -$47.49M | $8.28M | -$21.00M | -$21.87M | -$21.53M | -$20.67M | -$21.58M | -$20.85M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | $1.00K | $1.27K | N/A | N/A | N/A |
| Investing cash flow | -$104.00K | -$11.00K | -$153.00K | -$366.00K | -$133.00K | -$253.00K | -$64.00K | -$96.09K | -$24.74K | -$109.82K |
| Financing cash flow | -$217.00K | $29.32M | $14.87M | $23.11M | $35.22M | $76.18M | $17.11M | $16.98M | $18.81M | $15.78M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.18M | -$5.87M | -$5.29M | -$6.33M | -$5.39M | -$7.57M | -$5.75M | -$11.97M | -$7.97M | -$7.37M | -$7.49M | -$11.13M |
| Capital expenditures | $478.00K | $2.00K | $104.00K | $0 | $0 | $0 | $0 | $0 | $0 | $11.00K | $0 | $30.00K |
| Free cash flow | -$5.66M | -$5.87M | -$5.39M | -$6.33M | -$5.39M | -$7.57M | -$5.75M | -$11.97M | -$7.97M | -$7.38M | -$7.49M | -$11.15M |
Frequently Asked Questions About ATNM
What is Actinium Pharmaceuticals' annual revenue?
Actinium Pharmaceuticals reported revenue of $90.00K for the fiscal year ended Dec 31, 2025.
Is Actinium Pharmaceuticals profitable?
No. Actinium Pharmaceuticals reported net income of -$33.89M for the fiscal year ended Dec 31, 2025, with a net margin of -37652.2%.
How much free cash flow does ATNM generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$24.58M minus capital expenditures of $104.00K produced free cash flow of -$24.68M.
How much debt does Actinium Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $722.00K and cash and equivalents of $48.00M.
What is ATNM's profit margin?
For the fiscal year ended Dec 31, 2025, Actinium Pharmaceuticals reported gross margin of 100.0%, operating margin of -40274.4% and net margin of -37652.2%.
ATNM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors